World's Best Scientists 2026 revealed!
Mohamad Mohty

Mohamad Mohty

D-Index & Metrics

Medicine

D-Index
108
Citations
40976
World Ranking
6026
National Ranking
174

Mohamad Mohty publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mohamad Mohty sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,105 publications — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mohamad Mohty D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mohamad Mohty sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 108 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mohamad Mohty is a researcher affiliated with Inserm in France, primarily focused on the field of medicine with significant contributions to hematology. Their work spans a wide array of subfields including hematology, oncology, public health, molecular biology, and immunology.

The central themes in Mohty's research include hematopoietic stem cell transplantation and various hematological malignancies. Specific topics addressed in their publications cover:

  • Hematopoietic Stem Cell Transplantation
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Multiple Myeloma Research and Treatments
  • CAR-T Cell Therapy Research
  • Protein Degradation and Inhibitors
  • Polyomavirus and Related Diseases

Mohty has coauthored extensively with several frequent collaborators, indicating ongoing research partnerships. The most common coauthors include:

  • Arnon Nagler
  • Myriam Labopin
  • Fabio Ciceri
  • Didier Blaise
  • Éolia Brissot

In terms of publication venues, Mohty has appeared repeatedly in a number of specialized journals highlighting their research focus. Notable journals and the number of publications in each are:

  • Bone Marrow Transplantation (118 publications)
  • Blood (86 publications)
  • Transplantation and Cellular Therapy (22 publications)
  • American Journal of Hematology (19 publications)
  • Clinical Hematology International (18 publications)

Some of the recent papers associated with Mohamad Mohty's research portfolio include:

  • "Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease," 2020, published in New England Journal of Medicine
  • "Acute lymphoblastic leukaemia," 2020, published in The Lancet
  • "Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation," 2020, published in The Lancet Haematology
  • "Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results," 2023, published in Nature Medicine
  • "Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years," 2021, published in Bone Marrow Transplantation

Best Publications

  • Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

    Robert Zeiser;Nikolas von Bubnoff;Jason Butler;Mohamad Mohty

  • Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

    Jean-Luc Harousseau;Michel Attal;Hervé Avet-Loiseau;Gerald Marit

  • Mechanisms of action of antithymocyte globulin : T-cell depletion and beyond

    M Mohty

  • Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

    Olaf Penack;Monia Marchetti;Tapani Ruutu;Mahmoud Aljurf

  • Acute lymphoblastic leukaemia

    Florent Malard;Mohamad Mohty

  • The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

    Jan J. Cornelissen;Alois Gratwohl;Richard F. Schlenk;Jorge Sierra

  • Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories

    Régis Peffault de Latour;Jean Yves Mary;Célia Salanoubat;Louis Terriou

  • Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

    Aurore Perrot;Valerie Lauwers-Cances;Jill Corre;Jill Corre;Nelly Robillard

  • Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire

    Steven Le Gouill;Noel Milpied;Agnès Buzyn;Régis Peffault De Latour

  • Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

    T. Ruutu;A. Gratwohl;T. De Witte;B. Afanasyev

  • Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

    Jakob R. Passweg;Helen Baldomero;Christian Chabannon;Grzegorz W. Basak

  • Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

    Ibrahim Yakoub-Agha;Christian Chabannon;Peter Bader;Grzegorz W. Basak

  • Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey

    Dietger Niederwieser;Helen Baldomero;Jeff Szer;Michael Gratwohl

  • Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis

    Salut Brunet;Myriam Labopin;Jordi Esteve;Jan Cornelissen

  • Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.

    Reuben Benjamin;Reuben Benjamin;Charlotte Graham;Charlotte Graham;Deborah Yallop;Agnieszka Jozwik;Agnieszka Jozwik

  • Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019

    Rafael F. Duarte;Myriam Labopin;Peter Bader;Grzegorz W. Basak

  • Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission

    A Ruggeri;M Labopin;F Ciceri;M Mohty

  • Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia

    Olle Ringdén;Myriam Labopin;Gerhard Ehninger;Dietger Niederwieser

  • Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

    Celso A. Rodrigues;Guillermo Sanz;Claudio G. Brunstein;Jaime Sanz

  • CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT

    Martin Schmidt-Hieber;Myriam Labopin;Dietrich Beelen;Liisa Volin

Frequent Co-Authors

Myriam Labopin
Myriam Labopin Université Paris Cité
Arnon Nagler
Arnon Nagler Sheba Medical Center
Gérard Socié
Gérard Socié Université Paris Cité
Bipin N. Savani
Bipin N. Savani Vanderbilt University Medical Center
Ibrahim Yakoub-Agha
Ibrahim Yakoub-Agha University of Lille
Jan J. Cornelissen
Jan J. Cornelissen Erasmus University Rotterdam
Fabio Ciceri
Fabio Ciceri Vita-Salute San Raffaele University
Mauricette Michallet
Mauricette Michallet University of Helsinki
Nicolaus Kröger
Nicolaus Kröger Universität Hamburg
Christoph Schmid
Christoph Schmid University of Augsburg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare degrees online can open diverse career opportunities for students interested in medicine. For those aiming at leadership roles, affordable online mha programs offer flexibility and cost-effectiveness while preparing graduates for hospital and clinical management positions.

Advanced practitioners such as nurse leaders and educators can benefit from the cheapest online dnp programs, which focus on clinical excellence and healthcare innovation. Pharmacy is another in-demand field, and studying through a pharmacy degree online enables working professionals to advance without putting their careers on hold.

For those interested in health data, rhia certification programs online allow students to qualify for roles in medical information management and healthcare technology oversight. Each pathway offers distinctive benefits, affordability, and the convenience of online learning, making them appealing options for students charting their future in healthcare.

Best Scientists Citing Mohamad Mohty

Trending Scientists

Recently Published Articles